- Home
- ACET vs SOL Comparison
ACET vs SOL Comparison
Compare ACET & SOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- SOL
- Stock Information
- Founded
- ACET 1947
- SOL 2005
- Country
- ACET United States
- SOL United States
- Employees
- ACET N/A
- SOL N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- SOL Semiconductors
- Sector
- ACET Health Care
- SOL Technology
- Exchange
- ACET Nasdaq
- SOL Nasdaq
- Market Cap
- ACET 111.9M
- SOL 98.5M
- IPO Year
- ACET N/A
- SOL 2008
- Fundamental
- Price
- ACET $0.58
- SOL $1.76
- Analyst Decision
- ACET Buy
- SOL Strong Buy
- Analyst Count
- ACET 4
- SOL 2
- Target Price
- ACET $8.50
- SOL $4.50
- AVG Volume (30 Days)
- ACET 1.8M
- SOL 150.9K
- Earning Date
- ACET 11-05-2025
- SOL 11-14-2025
- Dividend Yield
- ACET N/A
- SOL N/A
- EPS Growth
- ACET N/A
- SOL N/A
- EPS
- ACET N/A
- SOL N/A
- Revenue
- ACET N/A
- SOL $71,226,000.00
- Revenue This Year
- ACET N/A
- SOL N/A
- Revenue Next Year
- ACET N/A
- SOL $45.37
- P/E Ratio
- ACET N/A
- SOL N/A
- Revenue Growth
- ACET N/A
- SOL N/A
- 52 Week Low
- ACET $0.45
- SOL $1.04
- 52 Week High
- ACET $1.19
- SOL $2.30
- Technical
- Relative Strength Index (RSI)
- ACET 36.18
- SOL 31.15
- Support Level
- ACET $0.57
- SOL $1.76
- Resistance Level
- ACET $0.67
- SOL $1.82
- Average True Range (ATR)
- ACET 0.06
- SOL 0.04
- MACD
- ACET 0.00
- SOL -0.01
- Stochastic Oscillator
- ACET 26.97
- SOL 0.00
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has globalised Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. Majority of revenue is From Electricity Generation. The company operates in China, USA, Germany, UK, Spain, France, Poland, Italy, Hungary, Luxembourg. Majority of revenue is from Italy.